Dexcom Inc - DXCM STOCK NEWS

Dexcom, a leader in real-time continuous glucose monitoring (CGM), announced the integration of its Dexcom G6 CGM with the Omnipod® 5 Automated Insulin Delivery (AID) System in the Netherlands. This deployment aims to improve diabetes management for the 100,000 individuals with Type 1 diabetes in the country, including 10,000 children. The system is the first tubeless Hybrid Closed Loop (HCL) approved for children in the Netherlands and promises significant health benefits, including increased time in range (+11.5%) and reduced HbA1c levels. The Dexcom G6 is highly water-resistant and allows remote monitoring via the 'Follow' app, giving users and caregivers more flexibility and peace of mind. The Dexcom G6 is reimbursed by Dutch health insurers for children (18 and under), pregnant women, women trying for pregnancy, and Type 1 hypo unaware users.

Dexcom presented significant clinical data at the ADA 2024 conference, emphasizing the benefits of Dexcom CGM for people with Type 2 diabetes. The data highlights meaningful decreases in A1C and improved time in range for users of Dexcom CGM. Dexcom introduced new integrations with the Omnipod 5 Automated Insulin Delivery System and showcased updates to the Dexcom G7 app, including direct connectivity to Apple Watch. Dexcom G7's enhanced Bluetooth range and rapid reconnect features further enhance user experience. The studies also indicate that CGM is beneficial even for Type 2 diabetes patients not on insulin and those with prediabetes, demonstrating improved health behaviors and psychosocial health.

Dexcom has announced that its G7 Continuous Glucose Monitoring (CGM) System now connects directly to Apple Watch in the U.S. This integration allows users to receive real-time glucose readings on their wrist without needing their iPhone. Dexcom G7 is the first CGM system to offer this feature, enhancing convenience and flexibility in diabetes management. The feature is available in the U.S., U.K., and Ireland, with more regions to follow. Users must have the Dexcom G7 app version 2.1, Apple Watch Series 6 or later on watchOS 10 or later, and an iPhone with iOS 17 or later.

Dexcom, a leader in continuous glucose monitoring (CGM) technology, announced that its Dexcom ONE sensor will now be reimbursed for around 100,000 Type 2 diabetes (T2D) patients in France. This decision allows individuals over 2 years old, on non-intensified insulin therapy, and with HbA1c ≥ 8% to access this technology. France becomes the first European country to offer full national reimbursement for CGM for T2D patients. This follows similar moves in the USA and New Zealand. Further, Germany's KKH health insurance provider has also started reimbursing Dexcom sensors for T2D patients. Dexcom's survey in the UK revealed that 63% of T2D patients face challenges in managing their condition, and 83% are open to using CGM technology. With T2D diagnoses rising globally, the adoption of CGM technology like Dexcom's could improve management and reduce healthcare costs.

Dexcom announced that Nova Scotia now provides coverage for Dexcom G6 and G7 continuous glucose monitoring (CGM) systems for residents with type 1 or type 2 diabetes who use intensive insulin and meet eligibility criteria.

This is part of the province's Pharmacare programs and a new income-based Sensor-Based Glucose Monitoring Program, aimed at reducing out-of-pocket costs for diabetes management tools.

Nova Scotia joins other provinces like New Brunswick, Newfoundland and Labrador, British Columbia, Manitoba, and Prince Edward Island in offering such coverage.

Dexcom's CGM systems, including the newly introduced G7, are clinically proven to reduce A1C, improve time in range, and reduce hypoglycemic events.

Dexcom (NASDAQ: DXCM) announced that its Executive Vice President and Chief Financial Officer, Jereme Sylvain, will present an update at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th.

The presentation will start at 4:20 PM EST and will be available via live webcast. The webcast can be accessed through the Dexcom Investor Relations website and will be archived for future reference.

Tandem Diabetes Care announced the compatibility of its Tandem Mobi insulin pump with both Dexcom G7 and G6 CGM systems.

This integration enhances user flexibility, allowing choice in diabetes management. Tandem Mobi, the smallest automated insulin delivery system, launched in the U.S. earlier in 2023, offers greater discretion and comfort.

Users will receive free software updates for this feature via email. New pumps will ship with the updated software pre-loaded.

This move strengthens Tandem's partnership with Dexcom and builds on their decade-long collaboration in providing innovative diabetes solutions.

Dexcom has launched the Dexcom ONE+ sensor in the UK, incorporating 25 years of research to assist individuals with Type 2 diabetes in monitoring their glucose levels in real-time. The first-ever 'Dexcom State of Type 2 Report' reveals that a significant number of people with Type 2 diabetes experience anxiety and depression, and many struggle to manage their condition effectively. The report highlights that 54% of respondents wish they had more confidence in managing their diabetes, and 63% face challenges in improving their diet or mental health. Additionally, 48% of participants believe glucose monitoring could improve their condition management.

Dexcom ONE+ aims to provide a tailored solution for people with Type 2 diabetes, enhancing user motivation and diabetes management by providing real-time feedback. The report is intended to serve as a resource for healthcare professionals and empower those with Type 2 diabetes to feel less isolated.

Dexcom, Inc. (Nasdaq: DXCM) reported strong financial results for the first quarter of 2024, with revenue growing 24% year-over-year to $921.0 million. The company's U.S. and international revenue also saw significant growth. Dexcom received FDA clearance for its new CGM system, launched new products in European countries, and published its annual Sustainability Report. The company's operating income and net income showed substantial increases, reflecting a positive outlook for the future.